Zenith Capital任命卡尔加里律师Bryan Ede为董事会成员,接替即将退休的董事Norman Wong博士。 Zenith Capital appointed Calgary lawyer Bryan Ede to its board, replacing retiring director Dr. Norman Wong.

Zenith Capital Corp.于2026年3月3日任命J.D.Bryan R. Ede为董事会董事,接任即将退休的董事,M.D.Norman Wong博士。 Zenith Capital Corp. appointed Bryan R. Ede, J.D., to its Board of Directors on March 3, 2026, succeeding retiring director Dr. Norman Wong, M.D. Ede是一名具有27年以上经验的卡尔加里商业律师,曾担任McMillan LLP和Miller Thomson LLP的股权合伙人,担任包括卡尔加里管理合伙人和法律实践小组主席在内的领导职务。 Ede, a Calgary-based commercial lawyer with over 27 years of experience, previously served as an equity partner at McMillan LLP and Miller Thomson LLP, holding leadership roles including Calgary Managing Partner and Chair of legal practice groups. 他的专门知识涵盖医疗保健、房地产、零售、石油和天然气,重点是交易和战略商务事项。 His expertise spans healthcare, real estate, retail, and oil and gas, with a focus on transactional and strategic business matters. 该公司的子公司Zenith Epigenetics Ltd正在开发癌症治疗技术,包括临床试验中的ZEN-3694, 该公司指出,其前瞻性陈述存在风险和不确定性。 The company, whose subsidiary Zenith Epigenetics Ltd. is developing cancer therapeutics, including ZEN-3694 in clinical trials, noted that its forward-looking statements are subject to risks and uncertainties.